Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
NCT ID: NCT00108836
Last Updated: 2010-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
400 participants
INTERVENTIONAL
2005-03-31
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Experimental Medication For the Treatment of Generalized Anxiety Disorder
NCT00097708
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860
A Dose-Response Safety Study of ENX-102 in Patients With GAD
NCT06653296
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
NCT00214994
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236054
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XBD173
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In need of psychiatric treatment
* Willingness to complete all aspects of the study
Exclusion Criteria
* History of schizophrenia or schizoaffective disorders
* Drug dependence within 2 months prior to study start
For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:
www.novartisclinicaltrials.com
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational Site
Anaheim, California, United States
Investigational Site
Los Angeles, California, United States
Investigational Site
Newport Beach, California, United States
Investigational Site
Redlands, California, United States
Investigational Site
San Diego, California, United States
Investigational Site
Fort Meyers, Florida, United States
Investigational Site
St. Petersburg, Florida, United States
Investigational Site
West Palm Beach, Florida, United States
Investigational Site
Atlanta, Georgia, United States
Investigational Site
Hoffman Estates, Illinois, United States
Investigational Site
Oak Brook, Illinois, United States
Investigational Site
Overland Park, Kansas, United States
Investigational Site
Dayton, Ohio, United States
Investigational Site
Portland, Oregon, United States
Investigational Site
Madison, Tennessee, United States
Investigational Site
Memphis, Tennessee, United States
Investigational Site
Edmonton, Alberta, Canada
Investigational Site
Kelowna, British Columbia, Canada
Investigational Site
Hamilton, Ontario, Canada
Investigational Site
Ottawa, Ontario, Canada
Investigational Site
Toronto, Ontario, Canada
Investigational Site
Montreal, Quebec, Canada
Investigational Site
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CXBD173A2204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.